Clinical Trial Update: Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing CT-P42 with Eylea in diabetic macular edema has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• CT-P42 (CT-P42)
• EYLEA (Aflibercept)

Snippet

Sponsor: Celltrion | Conditions: Diabetic Macular Edema (DME) | Phase 3 | Status: COMPLETED | Results posted: 2023-12-05